LATS2 and sarcoma: GMD expression was strongly correlated with methylation of multiple components of the Hippo signaling pathway [122] (Additional files 8, 9: Tables 8 and S9; Additional file 19: Data S1), including YAP1 in stomach adenocarcinoma (STAD), WWTR1 (TAZ) in STAD, NSCLC, breast cancer, sarcoma, CLLE, and COAD/READ, TEAD1 in CLLE, TEAD2 in glioma and SCLC, LATS1 in CLLE, LATS2 in mature B-cell lymphoma, and MST1 in CLLE.